Ultragenyx Signs $400M Royalty Purchase Agreement

Ultragenyx Pharmaceutical ( (RARE) ) just unveiled an announcement.

On November 3, 2025, Ultragenyx Pharmaceutical entered into a Royalty Purchase Agreement with OCM LS23 Holdings LP, an investment vehicle of OMERS, for $400 million in cash. This agreement grants OMERS the right to receive a portion of future royalty payments from Crysvita® sales in the U.S. and Canada, with payments starting in January 2028. The deal aims to bolster Ultragenyx’s balance sheet ahead of pivotal milestones, including multiple late-stage data readouts and regulatory submissions. The company reported a 15% revenue growth for the third quarter of 2025 and reaffirmed its 2025 revenue guidance, expecting total revenues between $640 million to $670 million.

The most recent analyst rating on (RARE) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Ultragenyx Pharmaceutical stock, see the RARE Stock Forecast page.

Spark’s Take on RARE Stock

According to Spark, TipRanks’ AI Analyst, RARE is a Neutral.

Ultragenyx Pharmaceutical’s overall stock score is driven by financial performance challenges, including ongoing losses and negative cash flow. While technical indicators show positive momentum, the valuation is impacted by a negative P/E ratio. The earnings call provided optimistic guidance with strong revenue growth and clinical progress, but financial losses remain a concern.

To see Spark’s full report on RARE stock, click here.

More about Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases. The company operates globally with multiple products, including Crysvita® and Dojolvi®, and is engaged in advancing its late-stage clinical pipeline.

Average Trading Volume: 1,524,217

Technical Sentiment Signal: Sell

Current Market Cap: $3.23B

Find detailed analytics on RARE stock on TipRanks’ Stock Analysis page.